Announced Date: 2025-05-29 (May 29, 2025)
Asset Name: XNW27011
Licensor: Evopoint (Evopoint Biosciences Co., Ltd., China)
Licensee (Buyer): Astellas (Astellas Pharma Inc., Japan)
.
Asset Modality: ADC (antibody drug conjugate)
Asset Target: CLDN18.2
Potential Indication: solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer
Current Stage: Phase I/II, in China
.
Scope of Authority:
Evopoint has granted Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 .
.
Deal Detail:
Upfront payment of $130 million,
Near-term payment up to $70 million,
Milestone payments up to $1.34 billion.
Tiered royalties on net sales.
.
Link:
